Physician
Hematology
Dr. Mark G. Carmichael, MD
|
|
Give Review
Mark Carmichael practices Hematology. He researched medicine at Uniformed Services University of the Health Sciences. Uniformed Services University of the Health Sciences is ranked 72 in research and 47 in primary care medicine Mark G. Carmichael is a published doctor as well. He has 16 publications published. The latest was: AE37: a novel T-cell-eliciting vaccine for breast cancer.
Publications
- Clinical and immunologic responses of HLA-A3+ breast cancer patients vaccinated with the HER2/neu-derived peptide vaccine, E75, in a phase I/II clinical trial.
- Results of the first phase 1 clinical trial of the HER-2/neu peptide (GP2) vaccine in disease-free breast cancer patients: United States Military Cancer Institute Clin...
- The impact of HER2/neu expression level on response to the E75 vaccine: from U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02.
- Longterm followup assessment of a HER2/neu peptide (E75) vaccine for prevention of recurrence in high-risk prostate cancer patients.
- Optimal dose and schedule of an HER-2/neu (E75) peptide vaccine to prevent breast cancer recurrence: from US Military Cancer Institute Clinical Trials Group Study I-01...
- Results of the first phase I clinical trial of the novel II-key hybrid preventive HER-2/neu peptide (AE37) vaccine.
- Central nervous system anaplastic large cell lymphoma in an adult: successful treatment with a combination of radiation and chemotherapy.
- The demonstration of pulmonary neuroendocrine cell hyperplasia with tumorlets in a patient with chronic cough and a history of multiple medical problems.
- A 59-year-old woman with tuberculous meningitis masked by hepatic encephalopathy.
- Metastatic malignant teratoma arising from mediastinal nonseminomatous germ cell tumor: a case report.
- Monitoring circulating tumor cells in cancer vaccine trials.
- AE37: a novel T-cell-eliciting vaccine for breast cancer.
- Comparison of different HER2/neu vaccines in adjuvant breast cancer trials: implications for dosing of peptide vaccines.
- Circulating regulatory T cells (CD4+CD25+FOXP3+) decrease in breast cancer patients after vaccination with a modified MHC class II HER2/neu (AE37) peptide.
- Assessment of immunologic response and recurrence patterns among patients with clinical recurrence after vaccination with a preventive HER2/neu peptide vaccine: from U...
Schools
Uniformed Services University of The Health Sciences
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Education
-
National Capital Consortium -
William Beaumont Army Medical Center -
Uniformed Services University of the Health Sciences
Helpful Reviews
Similar Doctors
|
|
Dr. Susan L. Kelley, MD |
|
|
Dr. Taying Yang, MD
 This Doctor is OpenDoctor Recommended.
|